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malignancy, which arises from the parafollicular C cells and
accounts for 5e10% of all the thyroid cancers. Recently, a
systematic review of 24 autopsy series revealed a preva-
lence rate of 0.14% of occult MTC in unselected autopsies.1
The incidence of MTC peaks during the 5th decade of life
and approximately 75% of MTCs are sporadic. Inherited MTC
is also associated with multiple endocrine neoplasia type 2A
(MEN 2A), MEN 2B, and familial MTC and, in addition, the
aggressiveness of the disease also varies. Although the 10-
year disease-specific survival rates for Stage I, II, III, and IV
are 100%, 93%, 71%, and 21%,2 respectively, there is no
significant improvement over the past 3 decades.3 Identi-
fying methods for early detection and ways to improve
clinical outcome are therefore most important.
MTC cells have been known to secrete many proteins
that can be used as biomarkers. From a clinical point
of view, calcitonin and carcinoembryonic antigen (CEA)
are the most useful proteins. Previous studies have
revealed correlations among the levels of calcitonin and
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versial because of the concerns surrounding assay meth-
odology, sensitivity, specificity, and cost effectiveness.4
The postoperative calcitonin level was found to be
strongly associated with the prognosis of patients and used
for follow-up. Compared with CEA, calcitonin level after
the operation drops more quickly and usually achieves nadir
in several weeks.
In Taiwan, many people undergo self-paid health
examination annually. The items often include many tumor
markers, such as CEA, CA 19-9, but do not include the
examination of thyroid sonography. It is not uncommon for
patients with an elevated CEA level to undergo colonoscopy
and esophagogastroduodenoscopy several times without
evidence of gastrointestinal malignancy, only to be diag-
nosed with MTC eventually.
Herein, we present five cases (3 males and 2 females;
mean age: 63 years old) diagnosed with MTC. The patients
underwent total thyroidectomy with neck lymph node
dissection in National Taiwan University Hospital between
September2010andJuly 2012, andwere curedof thedisease.
As shown in Fig. 1A, the level of calcitonin dropped
immediately after the operation, and CEA slowly returned
to the normal level as shown in Fig. 1B. Therefore, we
conclude that when the routine health examination finds
elevated CEA levels, an evaluation of the calcitonin level
and thyroid ultrasonography should also be done. In addi-
tion, calcitonin is a faster marker than CEA in the predic-
tion of cure for MTC.& Formosan Medical Association. All rights reserved.
Figure 1 Relationship between (A) serum levels of calcitonin and (B) carcinoembryonic antigen (CEA) and time after operation.
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